Company Filing History:
1 out of 27 
1 out of 41 Years Active: 2012
Title: Bernhard O Noll: Innovator in Immunostimulatory Oligonucleotides
Introduction
Bernhard O Noll is a notable inventor based in Neuss, Germany. He has made significant contributions to the field of immunology through his innovative work on oligonucleotide analogs. His research focuses on enhancing immunostimulatory potency, which has important implications for vaccine development and immune response.
Latest Patents
Noll holds a patent for "C-class oligonucleotide analogs with enhanced immunostimulatory potency." This invention relates to a class of CpG immunostimulatory oligonucleotides that contain a CpG immunostimulatory motif and a second motif capable of forming secondary structures, including duplex and higher-order structures, both in vitro and in vivo. The oligonucleotides developed by Noll are useful as adjuvants in vaccination and for inducing immune responses, including the expression of type I interferon (IFN) and gamma interferon (IFN-γ). Additionally, these oligonucleotides have potential applications in treating various conditions, such as allergies, asthma, infections, and cancer.
Career Highlights
Throughout his career, Bernhard O Noll has worked with prominent companies in the pharmaceutical industry, including Coley Pharmaceutical GmbH and Coley Pharmaceutical Group, Inc. His work has been instrumental in advancing the understanding and application of immunostimulatory oligonucleotides.
Collaborations
Noll has collaborated with esteemed colleagues, including Eugen Uhlmann and Jörg Vollmer, contributing to the collective advancement of research in immunology and oligonucleotide technology.
Conclusion
Bernhard O Noll's innovative work in the field of immunostimulatory oligonucleotides has the potential to significantly impact vaccine development and therapeutic strategies for various diseases. His contributions continue to shape the landscape of immunology and biotechnology.